Agios Pharmaceuticals Inc. Common Stock (AGIO)
Stock · NASDAQ · Health Care
$31.37as of 10/16/2026
Price chart
Active signals
AGIO Signal Track Record
How signals performed across all stocks →What AGIO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | +2.7% | 57% | October 8, 2026 |
| Bollinger Band Breakout | 26 | -3.3% | 35% | September 22, 2026 |
| 200-Day Moving Average TouchActive now | 19 | -0.3% | 47% | October 5, 2026 |
| Bollinger Band Breakdown | 18 | +5.1% | 67% | October 2, 2026 |
| Any 20-session window (baseline) | +1.4% | 55% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disea…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 539
- Website
- www.agios.com/
Fundamentals
- 1-day range
- $31.16$32.35
- Market cap
- $1.91B
- P/E (trailing)
- —
- P/E (forward)
- -7.79
- EPS (trailing)
- $-7.01
- Dividend yield
- —
- Beta
- 0.62
- Avg. volume
- 1.11M
How Agios Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Agios Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AGIOAgios Pharmaceuticals Inc. Common Stock$31.32▼ 3.09%Market cap $1.91BP/E —$22.24$46
- OCULOcular Therapeutix Inc. Common Stock$6.87▼ 6.91%Market cap $1.92BP/E —$6.23$16.44
- ABCLAbCellera Biologics Inc. Common Shares$11.8▼ 6.94%Market cap $1.92BP/E —$2.75$15.02
- NAMSWNewAmsterdam Pharma Company N.V. Warrant$9▼ 17.81%Market cap $1.87BP/E —$9.79$30.45
- ANIPANI Pharmaceuticals Inc.$72.29▲ 0.01%Market cap $1.86BP/E 15.16$69.58$97
- DMRADamora Therapeutics Inc. Ordinary Shares$18.44▼ 1.60%Market cap $1.84BP/E —$16.5$34.89
- NBTXNanobiotix S.A. American Depositary Shares$21.3▼ 4.18%Market cap $1.83BP/E —$13.1$47.66
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals Inc. Common Stock | $1.91B | — | $31.32 | ▼ 3.09% | $22.24$46 |
| OCUL Ocular Therapeutix Inc. Common Stock | $1.92B | — | $6.87 | ▼ 6.91% | $6.23$16.44 |
| ABCL AbCellera Biologics Inc. Common Shares | $1.92B | — | $11.8 | ▼ 6.94% | $2.75$15.02 |
| NAMSW NewAmsterdam Pharma Company N.V. Warrant | $1.87B | — | $9 | ▼ 17.81% | $9.79$30.45 |
| ANIP ANI Pharmaceuticals Inc. | $1.86B | 15.16 | $72.29 | ▲ 0.01% | $69.58$97 |
| DMRA Damora Therapeutics Inc. Ordinary Shares | $1.84B | — | $18.44 | ▼ 1.60% | $16.5$34.89 |
| NBTX Nanobiotix S.A. American Depositary Shares | $1.83B | — | $21.3 | ▼ 4.18% | $13.1$47.66 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Agios Pharmaceuticals (AGIO) Could Be 28% Undervalued Following Its November Results Call DateYahoo · 10/10/2026
- Agios Pharmaceuticals (AGIO) Stock Looks Fully Priced Against Current SalesYahoo · 10/9/2026
- Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ETYahoo · 10/8/2026
- Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37benzinga · 10/7/2026
- Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $37Benzinga · 10/7/2026
- AGIO Stock Sinks 29% in Three Months: Here's What You Need to KnowYahoo · 10/6/2026
- Agios' Growth Story Hinges on Mitapivat's Commercial ExpansionYahoo · 10/2/2026
- 10 Health Care Stocks Whale Activity In Today’s SessionBenzinga · 9/29/2026
- B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50Benzinga · 9/21/2026
Insider Activity
Insider Actions →- Gheuens Sarah · August 4, 2026 · Sale30.0K @ $30.48
- Backstrom Jay T. · July 8, 2026 · Option Exercise1.4K
- Backstrom Jay T. · July 8, 2026 · Grant1.4K
- Gheuens Sarah · July 1, 2026 · Option Exercise8.4K
- Gheuens Sarah · July 1, 2026 · Sale4.0K @ $37.56
- Smith Cynthia · June 18, 2026 · Option Exercise2.8K
- Burns James William · June 18, 2026 · Option Exercise3.0K
- Gheuens Sarah · June 18, 2026 · Grant3.0K
- Gheuens Sarah · June 18, 2026 · Option Exercise3.0K
- Jones Cecilia · June 18, 2026 · Grant3.0K
- Smith Cynthia · June 18, 2026 · Grant2.9K
- Jones Cecilia · June 18, 2026 · Option Exercise3.0K
- Milanova Tsveta · June 18, 2026 · Grant3.0K
- Milanova Tsveta · June 18, 2026 · Option Exercise3.0K
- Backstrom Jay T. · June 18, 2026 · Grant14.9K
Institutional Ownership
March 31, 2026
- Total shares held
- 63.79M
- Total value held
- $2.02B
- Institutional holders
- 227
- Unknown5.92M
- Unknown5.75M
- Unknown5.68M
- Unknown3.36M
- Unknown2.70M
- Unknown2.68M
- Unknown2.63M
- Unknown2.61M
- Unknown1.58M
- Unknown1.56M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
AGIO Valuation Concerns Ahead of Q3 2026 Call
AGIO’s November earnings call sparked debate that the shares might be undervalued by about 28%, while analysts noted the stock appears fully priced against current sales. The company will host its third‑quarter 2026 results call on Nov. 5, which could clarify expectations. After a 29% decline over three months, Truist Securities lowered its target price to $37, reflecting a more cautious view.
AGIO Valuation Concerns Ahead of Q3 2026 Call. AGIO’s November earnings call sparked debate that the shares might be undervalued by about 28%, while analysts noted the stock appears fully priced against current sales. The company will host its third‑quarter 2026 results call on Nov. 5, which could clarify expectations. After a 29% decline over three months, Truist Securities lowered its target price to $37, reflecting a more cautious view.